Table 1.

The uptake of ⁶⁴Cu-NOTA-FSHR-mAb in different tissues based on ROI analysis (n = 3)

	Tumor (%ID/g)	Liver (%ID/g)	Blood (%ID/g)	Muscle (%ID/g)
4 h p.i.
CAOV-3	3.6 ± 0.8	16.4 ± 0.5	14.2 ± 1.1	1.0 ± 0.2
SKOV-3	2.3 ± 1.2	14.5 ± 0.9	19.5 ± 0.7	0.9 ± 0.01
MDA-MB-231	7.3 ± 1.0	17.4 ± 1.7	14.1 ± 1.2	0.9 ± 0.1
PC-3	2.9 ± 0.9	16.7 ± 1.4	12.1 ± 1.6	0.9 ± 0.1
24 h p.i.
CAOV-3	13.2 ± 0.7	14.6 ± 0.8	10.0 ± 3.0	0.8 ± 0.1
SKOV-3	8.0 ± 0.9	10.2 ± 0.6	10.1 ± 0.6	0.9 ± 0.03
MDA-MB-231	11.5 ± 1.2	15.6 ± 1.4	9.0 ± 1.3	0.5 ± 0.1
PC-3	9.1 ± 0.7	13.6 ± 0.7	8.7 ± 1.0	0.8 ± 0.2
48 h p.i.
CAOV-3	14.6 ± 0.4	11.2 ± 2.0	6.3 ± 0.6	0.4 ± 0.2
SKOV-3	9.1 ± 1.3	8.5 ± 0.4	7.9 ± 0.6	0.1 ± 0.02
MDA-MB-231	12.4 ± 0.9	13.1 ± 1.0	6.1 ± 0.7	0.2 ± 0.04
PC-3	10.5 ± 0.8	11.3 ± 1.0	6.3 ± 0.6	0.3 ± 0.2